Assessment of Cognitive Scales to Examine Memory, Executive Function and Language in Individuals with Down Syndrome: Implications of a 6-month Observational Study

Liogier d'Ardhuy, Xavier and Edgin, Jamie O. and Bouis, Charles and de Sola, Susana and Goeldner, Celia and Kishnani, Priya and Nöldeke, Jana and Rice, Sydney and Sacco, Silvia and Squassante, Lisa and Spiridigliozzi, Gail and Visootsak, Jeannie and Heller, James and Khwaja, Omar (2015) Assessment of Cognitive Scales to Examine Memory, Executive Function and Language in Individuals with Down Syndrome: Implications of a 6-month Observational Study. Frontiers in Behavioral Neuroscience, 9. ISSN 1662-5153

[thumbnail of pubmed-zip/versions/2/package-entries/fnbeh-09-00300-r1/fnbeh-09-00300.pdf] Text
pubmed-zip/versions/2/package-entries/fnbeh-09-00300-r1/fnbeh-09-00300.pdf - Published Version

Download (1MB)

Abstract

Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development) and adaptive behavior. Previous pharmacological studies in this population have been limited by a lack of appropriate endpoints that accurately measured change in cognitive and functional abilities. Therefore, the current longitudinal observational study assessed the suitability and reliability of existing cognitive scales to determine which tools would be the most effective in future interventional clinical studies. Subtests of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Cambridge Neuropsychological Test Automated Battery (CANTAB), and Clinical Evaluation of Language Fundamentals-Preschool-2 (CELF-P-2), and the Observer Memory Questionnaire-Parent Form (OMQ-PF), Behavior Rating Inventory of Executive Function®–Preschool Version (BRIEF-P) and Leiter International Performance Scale-Revised were assessed. The results reported here have contributed to the optimization of trial design and endpoint selection for the Phase 2 study of a new selective negative allosteric modulator of the GABAA receptor α5-subtype (Basmisanil), and can be applied to other studies in the DS population.

Item Type: Article
Subjects: Middle East Library > Biological Science
Depositing User: Unnamed user with email support@middle-eastlibrary.com
Date Deposited: 08 Mar 2023 11:54
Last Modified: 31 Jul 2024 13:41
URI: http://editor.openaccessbook.com/id/eprint/283

Actions (login required)

View Item
View Item